

10-17-03

Docket 17566 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: PETER G. BAKHIT, et al.,)	Examiner:
)	
Serial Number: 10/621,053)	
)	Art Unit:
Filed: July 15, 2003)	
)	Confirmation No.
For: OPTHALMIC COMPOSITIONS)	
COMPRISING TREFOIL FACTOR)	
FAMILY PEPTIDES)	
<hr/>		Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicants provide with regard to the above-identified patent application entitled OPTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 3 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material

documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,



Date: October 15, 2003

Brent A. Johnson
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date October 15, 2003 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV295682381US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew

Name of person mailing paper




Signature of person signing paper

Date October 15, 2003

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17566 (AP)		SERIAL NO.: 10/621,053
APPLICANT: PETER G. BAKHIT, et al.		TITLE: OPHTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES
FILING DATE: July 15, 2003		GROUP:



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicabl)
	AA	2002/0119104 A1	8/29/02	Rosenthal, et al.			
	AB	5,620,921	4/15/97	Sullivan			
	AC	5,652,209	7/29/97	Pflugfelder, et al.			
	AD	5,688,765	11/18/97	Sullivan			
	AE	5,958,912	9/28/99	Sullivan			
	AF	5,981,607	11/9/99	Ding, et al.			
	AG	5,900,407	5/4/99	Yerxa, et al.			
	AH	6,063,755	5/16/00	Podolsky			
	AI	6,107,289	8/22/00	Sullivan			
	AJ	6,153,607	11/28/00	Pflugfelder, et al.			
	AK	6,221,840	4/24/01	Podolsky			
	AL	6,277,855	8/21/01	Yerxa			
	AM	6,316,218 B1	11/13/01	Podolsky			
	AN	6,319,908	11/20/01	Yerxa, et al.			
	AO	6,323,187	11/27/01	Yerxa, et al.			
	AP	6,331,529	12/18/01	Yerxa, et al.			
	AQ	6,348,589	2/19/02	Pendergast, et al.			
	AR	6,436,910	8/20/02	Yerxa, et al.			
	AS	6,455,583 B1	9/24/02	Pflugfelder, et al.			
	AT	6,525,018	2/25/03	Podolsky			
	AU	6,548,658 B2	4/15/03	Yerxa			
	AV	6,555,675	4/29/03	Rideout, et al.			

FOREIGN PATENT DOCUMENTS


		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
	BA	WO 02/085402	10/31/02	PCT			
	BB	WO 02/102399 A2	12/27/02	PCT			

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17566 (AP)	SERIAL NO.: 10/621,053
APPLICANT: PETER G. BAKHIT, et al.	TITLE: OPHTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES
FILING DATE: July 15, 2003	GROUP:



	BC	WO 02/102403	12/27/02	PCT			
	BD	WO 02/46226 A2	6/13/02	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Allen, et al., The mucus barrier, its role in gastroduodenal mucosal protection, <i>J. Clin Gastroenterol</i> , 1998; 10 (Suppl1): S93-S98;
	CB	Babyatsky, M.W., et al., Oral trefoil peptides protect against ethanol-and indomethacin-induced gastric injury in rats, <i>Gastroenterology</i> , 1996, Vol. 110, pp. 489-497
	CC	Carr, M. D., et al., Solution Structure Studies of Trefoil factor family proteins, <i>Univ. of Kent</i> , 3 pgs, www.biochem.ucl.ac.uk
	CD	Corfield, A.P., et al., Ocular mucins: purification, metabolism and functions, <i>Progress in Retinal and Eye Research</i> , Vol. 16, No. 4, pp 627-656, 1997
	CE	Danjo, Y., et al., Alteration of mucin in human conjunctival epithelia in dry eye, <i>Invest Ophthalmol Vis Sci</i> , 1998, V 39, pp 2602-09
	CF	Dignass, A., et al., Trefoil peptides promote epithelial migration through a transforming growth factor β -independent pathway, <i>J. Clin. Invest.</i> 94, 376-383
	CG	Gipson, I.K., et al., Mucin genes expressed by the ocular surface epithelium, <i>Progress in Retinal and eye research</i> , Vol. 16, No. 1, pp. 81-98, 1997
	CH	Good, R.J., Surface free energy of solids and liquids: thermodynamics, molecular forces, and structures, <i>J. Colloid Interface Sci.</i> ; 1977, 59:398-419
	CI	Goke, M., et al., Trefoil peptides promote restitution of wounded corneal epithelial cells, <i>Experimental Cell Research</i> , 2001, V. 264, pp. 337-344
	CJ	Hauser, F., et al., Hp1.b, A human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus, <i>Proc Natl Acad Sci USA</i> , 1993, V. 90, pp. 6961-6965
	CK	Jagla, W., et al., Localizaton of TFF3 peptide to porcine conjunctival goblet cells, <i>Cell tissue res</i> (1999) 296:525-530
	CL	Langer, G., Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells, <i>Invest Ophthalmol Vis Sci</i> , 1999, V. 40, pp 2220-2224
	CM	Langer, G., Et Al., TFF Peptides, New Mucus-Associated Secretory Products Of The Conjunctiva, <i>Ophthalmologe</i> , 2001-98:976-979


EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17566 (AP)	SERIAL NO.: 10/621,053
APPLICANT: PETER G. BAKHIT, et al.	TITLE: OPHTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES
FILING DATE: July 15, 2003	GROUP:



	CN	Ligumsky, et al., Sucralfate protection against gastrointestinal damage: possible role of prostanoids, <i>Isr J Med Sci</i> 1986; 22:801-806
	CO	Paulsen, F.P., et al., TFF peptides in the human efferent tear ducts, <i>Invest Ophthalmol Vis Sci</i> , 2002, V 43, pp. 3359-3364
	CP	Playford, R.J., Trefoil peptides: what are they and what do they do?, <i>Journal of the Royal College of Physicians of London</i> , Vol. 31, pp. 37-40.
	CQ	Rachmilewitz, D., Trefoil peptides: a novel modality to prevent gastric injury?, <i>Gastroenterology</i> , Vol. 110, No. 2, pp. 632-635
	CR	Tabor, et al., Surface Forces and Surface Interactions, <i>J. Colloid Interface Sci</i> , 1977, 58:2-13
	CS	Tran, C.P., et al., Trefoil peptide TFF2 (spasmolytic polypeptide) potentially accelerates healing and reduces inflammation in a rat model of colitis, <i>OVID: Tran: Gut</i> , Vol. 44(5) May 1999, 636-642
	CT	Uebermuth, C., Mucins of the eye, <i>Ophthalmology</i> , 1999 – 96:563-569
	CU	Wong, W.M., et al., Trefoil Peptides, <i>Gut</i> , Vol. 44(6) June 1999, 890-895
	CV	Wright, G.R., et al., Trefoil factor family domain peptides, <i>Virchows arch</i> , 1997 431:299-304
	CW	Wright, N.A., Interaction of trefoil family factors with mucins: clues to their mechanism of action?, <i>Gut</i> , Vol. 48(3) March 2001, pp 293-294
	CX	Tearing and Dry Eyes, <i>Ocular Times, Eye News and Information</i> ; www.geocities.com/ocular_times/tearing.html , 2/14/03, 4 pgs.

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.